Archives
Please, enter cell line, author or any other phrase or word you would like to search for.
PHI Focuses on Biomanufacturing — Appoints New CEO and Chairman
The Board of Directors of PHI has appointed the company’s CFO, Patrik Eschricht, as the new CEO. In addition, the former CEO and founder of PHI, Peter Egelberg, has been appointed executive chairman of the Board.
2022 publication highlights
In 2022, researchers around the world published 34 publications featuring HoloMonitor. We are thrilled to see how HoloMonitor helps scientists around the world explore new areas of study and address questions from cancer research to neuroscience.
Interim Report 2 2022/23
The online sales and lead generation strategy continues to deliver. As a result, sales from August to October this year reached 2.7 KSEK — an increase of 50 % compared to any previous corresponding period.
BioStock: PHI on the alliance for cell-based biomanufacturing
Kersti Alm, CSO at PHI, visited BioStock’s studio to talk about the recently created alliance for advancing cell-based biomanufacturing and PHI’s pivotal role in the collaboration.
PHI Is Opening A New Development Office In The US
As a result of the newly created alliance for advancing cell-based biomanufacturing which was recently communicated, PHI is taking the next step in its investment into regenerative medicine by opening an office in the Innovation Quarter in Winston-Salem.
BioStock: PHI part of new regenerative medicine alliance
BioStock contacted Product Manager Lisa Lindström to learn more about PHI’s newly formed technology development alliance for regenerative medicine and what excites her about the future.
PHI, SAS, QIAGEN and BioSpherix form Alliance to Advance Cell-based Biomanufacturing
In association with the Wake Forest Institute for Regenerative Medicine, PHI, BioSpherix, analytics leader SAS and QIAGEN have created a technology development alliance to create the AI-based process control tools needed for automated biomanufacturing.
BioStock: PHI expands market potential with regenerative medicine opportunity
BioStock contacted CFO Patrik Eschricht to find out more about PHI’s visions regarding regenerative medicine, cell-based therapies and automatization of biomanufacturing.
Interim Report 1 2022/23
Despite a summer-sluggish period ending in July, sales were just one unit away from surpassing our best quarter ever; the same period last year.
Wake Forest Institute for Regenerative Medicine Welcomes PHI
PHI visits the WFIRM to finalize an agreement concerning the automation of advanced quality control in large-scale biomanufacturing of regenerative therapies.